**Plasmodium falciparum** Malaria in Children Aged 0-2 Years: The Role of Foetal Haemoglobin and Maternal Antibodies to Two Asexual Malaria Vaccine Candidates (MSP3 and GLURP)

David Tiga Kangoye¹, Issa Nebie¹, Jean-Baptiste Yaro¹, Siaka Debe¹, Safiatou Traore¹, Oumarou Ouedraogo¹, Guillaume Sanou¹, Issiaka Soulama¹, Amidou Diarra¹, Alfred Tiono¹, Kevin Marsh²,³, Sodiomon Bienvenu Sirima¹*, Philip Bejon²,³

¹Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso, ²Kenyan Medical Research Institute, Centre for Geographic Medicine Research (Coast), Kilifi, Kenya, ³Nuffield Department of Medicine, Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Oxford, United Kingdom

**Abstract**

**Background:** Children below six months are reported to be less susceptible to clinical malaria. Maternally derived antibodies and foetal haemoglobin are important putative protective factors. We examined antibodies to *Plasmodium falciparum* merozoite surface protein 3 (MSP3) and glutamate-rich protein (GLURP), in children in their first two years of life in Burkina Faso and their risk of malaria.

**Methods:** A cohort of 140 infants aged between four and six weeks was recruited in a stable transmission area of southwestern Burkina Faso and monitored for 24 months by active and passive surveillance. Malaria infections were detected by examining blood smears using light microscopy. Enzyme-linked immunosorbent assay was used to quantify total Immunoglobulin G to *Plasmodium falciparum* antigens MSP3 and two regions of GLURP (R0 and R2) on blood samples collected at baseline, three, six, nine, 12, 18 and 24 months. Foetal haemoglobin and variant haemoglobin fractions were measured at the baseline visit using high pressure liquid chromatography.

**Results:** A total of 79.6% of children experienced one or more episodes of febrile malaria during monitoring. Antibody titres to MSP3 were prospectively associated with an increased risk of malaria while antibody responses to GLURP (R0 and R2) did not alter the risk. Antibody titres to MSP3 were higher among children in areas of high malaria risk. Foetal haemoglobin was associated with delayed first episode of febrile malaria and haemoglobin CC type was associated with reduced incidence of febrile malaria.

**Conclusions:** We did not find any evidence of association between titres of antibodies to MSP3, GLURP-R0 or GLURP-R2 as measured by enzyme-linked immunosorbent assay and early protection against malaria, although anti-MSP3 antibody titres may reflect increased exposure to malaria and therefore greater risk. Foetal haemoglobin was associated with protection against febrile malaria despite the study limitations and its role is therefore worthy further investigation.

Citation: Kangoye DT, Nebie I, Yaro J-B, Debe S, Traore S, et al. (2014) *Plasmodium falciparum* Malaria in Children Aged 0-2 Years: The Role of Foetal Haemoglobin and Maternal Antibodies to Two Asexual Malaria Vaccine Candidates (MSP3 and GLURP). PLoS ONE 9(9): e107965. doi:10.1371/journal.pone.0107965

Editor: Érika Martins Braga, Universidade Federal de Minas Gerais, Brazil

Received May 9, 2014; Accepted August 7, 2014; Published September 19, 2014

Copyright: © 2014 Kangoye et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. The data supporting the findings described in this article are available on figshare.com. Serology: http://dx.doi.org/10.6084/m9.figshare.1010196; Monthly follow up data: http://dx.doi.org/10.6084/m9.figshare.1010195; Active case detection data: http://dx.doi.org/10.6084/m9.figshare.1010194; Passive case detection data: http://dx.doi.org/10.6084/m9.figshare.1010193; Homesteads coordinates: http://dx.doi.org/10.6084/m9.figshare.1010192; Baseline visit data: http://dx.doi.org/10.6084/m9.figshare.1010191.

Funding: This work was funded by the European and Developing Countries Clinical Trials Partnership, grant number IP.2008.31100.001 to the Malaria Vectored Vaccines Consortium (MVVC), and coordinated by the European Vaccine Initiative. PB is jointly funded by the UK Medical Research Council (MRC) and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The co-author Dr Philip Bejon has served as and is still an editorial member for PLOS ONE. This does not alter the authors’ adherence to PLOS ONE Editorial policies and criteria.

* Email: s.sirima.cnlp@gmail.com

These authors contributed equally to this work.
Introduction

Children under five years of age bear the majority of the malaria burden [1], however infants have been shown to be less likely to develop clinical malaria within their first six months of life [2–5].

This apparent protection has been linked to passive transfer of anti-malaria antibodies by earlier experimental studies [6–8]. A study in older children confirmed the protective effect of passive transfer of antibodies [9]. Other possible protective factors include foetal haemoglobin, as suggested by in vitro studies [10,11] and mouse models [12]. Rodent malaria experiments have provided evidence of the protective effect of a para-aminobenzoic acid-poor diet [13–16], which can be expected in exclusive breast-feeding. Breast milk constituents might also contribute to the protection of infants against malaria as suggested by in vitro studies [17]. Finally, studies also suggested that infants are less exposed to mosquito bites [18], thus reducing their risk of contracting malaria.

Correlates of protection of specific antibodies against malaria have been extensively studied in adults and children [19–32], however fewer studies have specifically addressed the risk of malaria in infancy. Anti-malaria antibodies present during infancy are initially passively received from the mother in utero (mainly IgG) [33], and then endogenously produced by the infant (IgM and IgG) as a response to repeated exposure to infective mosquito bites [34]. Nonetheless, it has been evidenced that earlier in life, some foetuses are able to mount an immune response to prenatal exposure [35] through transplacental transfer of soluble malaria antigens [35,36]. Most sero-epidemiological studies investigating these potential immune correlates of protection in infants did not find the hypothesised protective effect of antibodies to the individual antigens tested (CSP, LSA-1, crude schizont extract, MSP1, MSP2, Pf155/RESA and the vaccine candidate SPf66) [37–41]. However, two studies conducted independently in Liberia and Kenya [42,43] identified a protective effect of antibodies to MSP1–19.

We performed the present longitudinal prospective infant cohort study in the south-western region of Burkina Faso, where the transmission of malaria is high and stable. Our study aimed at investigating the role of transplacentally acquired anti-malaria antibodies, while adjusting for foetal haemoglobin and other factors, in the susceptibility of children to P. falciparum malaria in their first years of life. We specifically investigated three merozoite surface proteins, MSP3-LSP and two regions of GLURP (R0 and R2), as they have been used in a malaria vaccine that is currently ongoing testing [44,45].

Methods

Ethical consideration

This study was approved by the Institutional Review Board of Centre National de Recherche et de Formation sur le Paludisme (CNRFP) in Burkina Faso. The study was conducted according to the principles of the Declaration of Helsinki. Individual written informed consent was obtained from the parents of each child before any study procedure was performed. The parents who could not read and write in the language used in the informed consent form, signed the form with their thumb print after it was completed by an independent witness on their behalf. The IRB approved this consent procedure.

Study site

The study area is described elsewhere [46]. Briefly, the study area encompasses four health catchment areas served by four dispensaries reporting to Banfora health district. Two (Flantama and Korona) are located within Banfora town with water and power supply and mainly cement brick, iron sheet roofing houses. The other two (Nafona and Bounouna) are Banfora sub-urban villages with mainly adobe-walled, thatched roofing houses. The annual rainfall is above 900 mm with the rains lasting from May to October. The malaria incidence in children under five is 1.18 episodes/child/year using an active case detection [46] with Plasmodium falciparum being responsible for more than 90% malaria cases.

Study population

A cohort of 140 infants aged between four and six weeks was recruited into the study. The parents were informed of the study aims and procedures during the early post-natal visits at the dispensaries, prior to the children reaching one month of age. Recruitment was carried out simultaneously at the four health catchment areas of the study site from November 2010 to February 2011. Since measuring time to the first infection was one of the objectives of the study, infants who had either a documented previous episode of malaria or a positive blood smear at the baseline visit were excluded from the study; nevertheless, some infants might have had malaria infections that were unobserved. After the recruitment of the study participants, the geodetic coordinates (longitude, latitude) of their homesteads were recorded using Global Positioning System (GPS) devices. The approximate centre of each family compound was the reference point to record these coordinates.

Surveillance of malaria morbidity

To detect malaria infections, the children were followed up actively with weekly home visits and passively with dispensary monitoring for two years. The active follow-up consisted of weekly home visits performed by fieldworkers whose main tasks were to check the children’s health, collect blood samples and start anti-malarial treatment when indicated according to the National Malaria Control Program guidelines. The time window for the home visits was ±2 days. In the passive follow-up, the caregivers were encouraged to bring their children to the nearby dispensary or the clinical research unit at any time should the child appear unwell. In both surveillance methods a blood smear was collected in case of fever (i.e. a reported history of fever in the past 24 hours and/or axillary temperature ≥37.5°C). In addition, to monitor the occurrence of asymptomatic parasitaemia, bloods smears were systematically collected on a monthly basis until the detection of the first malaria infection regardless of the axillary temperature. The children who became ill over the course of the study received health care free of charge either at the dispensaries, the clinical research unit or the paediatric unit of the regional referral hospital when necessary.

Parasitological examination

Light microscopy was used to examine the blood smears, which were collected, air dried and GIE/MAA-stained as described elsewhere [46]. The parasite density of each blood smear was assessed by two independent microscopists and their results were compared for consistency. When their results were concordant, the average was recorded as the final result; otherwise a third microscopist was involved. The final result was the average of the two most concordant parasite densities.
Haemoglobin typing
High Pressure Liquid Chromatography (HPLC) was used to quantify the fractions of foetal haemoglobin and haemoglobin variants in the children.

Antibody quantification
Enzyme-linked immunosorbent assay (ELISA) was used to quantify anti-malaria total IgG in capillary blood samples collected by finger or heel prick at baseline, three, six, nine, 12, 18 and 24 months of follow up. Two P. falciparum blood-stage antigens MSP3-LSP [47], GLURP (R0 and R2) [48] were used in these assays. The ELISA was performed as described elsewhere [24].

Statistical analysis
Fever was defined as an axillary temperature $\geq 37.5^\circ$C and/or a reported history of fever in the past 24 hours. Malaria infection was defined as any positive parasitaemia regardless of the axillary temperature. Two definitions were set for febrile malaria; definition 1 included all febrile episodes with any level of asexual P. falciparum parasitaemia, and definition 2 included only febrile episodes associated with asexual P. falciparum parasite density $\geq 10000/\mu$L. This latter definition was derived after examining the distributions of the log-transformed parasite densities among children with and without fever in cross-sectional surveys (Figure S1). Febrile malaria episodes occurring within 21 days were considered a single episode.

The antibody titres expressed in arbitrary units were log-transformed to approximate a normal distribution. We fitted a multiple fractional polynomial regression of antibody titres on age to estimate the non-linear relationship between anti-malaria antibody titres and age. We fitted a linear regression model to estimate the relationship between a set of potential predictors and anti-malaria antibody titres. In this linear model, antibody titre was included as a time-changing outcome, i.e. the antibody titre measured at the end of each time interval within which malaria infections were recorded, and age as fractional polynomial covariate.

We adapted a previously published method for calculating exposure indexes (EI) to our cohort with time-to-event data [49]. An individual malaria exposure index (EI) was computed as the median time to the first malaria infection of the surrounding neighbours of each index child within a circle of a given radius around him/her at the middle of the circle. We found that a 1.5 km radius best predicted risk in our dataset (Figure S2). ELs were transformed to negative values so that the most exposed has the highest exposure index.

We fitted a Cox regression model to estimate the relationship between the time to first febrile malaria episode and a set of covariates of interest. We also fitted a negative binomial regression model to estimate the association between multiple malaria episodes and a set of potential explanatory covariates. Antibodies were fit in two ways; a) applying the baseline antibody titre throughout the period of monitoring and b) applying time-varying antibody titre, i.e. the antibody titre measured at the most recent time point, which therefore changed throughout the period of monitoring. The log likelihood ratio test was used to test the significance of variables with multiple levels. The assumption of proportional hazards for Cox regression was tested based on the Kaplan Meier method and the Schoenfeld residuals. The assumption of a linear effect of antibody titres on malaria episodes was investigated using fractional polynomial modelling. We used the Huber-White Sandwich estimator to adjust for clustering by individual in linear and negative binomial regression models. The data were analysed using Stata 13 (StataCorp, College Station, Texas).

Results
Study population characteristics
A total of 216 mothers of new-borns were invited to attend study screening visits during early post-natal visits at the four dispensaries of the study area. Of these, 148 (68.5%) attended the study screening visits with their infants. A total of 140 infants were recruited during a three-month period from mid-November 2010 to mid-February 2011. The baseline characteristics of the infants and their mothers are summarised in Table 1.

Follow-up of participants and malaria morbidity
Twenty-three children (16.4%) were lost to follow-up before completing 24 months with a median [Inter Quartile Range-IQR] follow up time of 9.8 [2, 14.75] months. Among them, six migrated out of the study area, 10 withdrew their consent, four died and three dropped out of the study and were no longer reachable.

One or more episodes of febrile malaria were experienced by 79.6% of all children during follow-up. Sixty-three children (45.98%) had at least one malaria infection in their first year of life and 46 (76.66%) of the remaining 60 children in their second year.

Anti-malaria antibody kinetics
Antibody titres from one time point were weakly to moderately correlated with antibodies at the next time point (rho ranging from -0.28 to 0.55; 0.31 to 0.58 and 0.15 to 0.60, respectively for anti-MSP3, anti-GLURP R0 and anti-GLURP R2 antibody titres) with the strongest correlations observed from baseline to month 3, and months 9 to 12 (Table S1). The time-course of individual antibody kinetics is shown in Figure S3. Anti-GLURP R0 and anti-GLURP R2 antibodies were more closely correlated to each other ($r = 0.52, p<0.001$) than either GLURP sub-unit antibody was correlated to anti-MSP3 antibody titres ($r = 0.35, p<0.001$ and $r = 0.4, p<0.001$ respectively).

Figure 1 shows individual antibody titres and a best-fit line using multiple fractional polynomials. There is an overall decline of anti-malaria total IgG titres to the three antigens from one to four months of age, presumably indicating the waning of maternally-derived anti-malaria antibodies. Thereafter, both the anti-GLURP R2 and anti-GLURP R0 total IgG titres rise slightly with increasing age while anti-MSP3 total IgG titres remain constant.

Predictive factors for the changing antibody titres
The univariate analysis of all potential covariates is displayed in Table S2. The final multi-variable model showed strong associations with age and season of measurement for each antigen tested (Table 2). In addition, associations were observed between the number of malaria episodes recorded immediately before the blood sample collection and the titres of antibodies to GLURP.

Antibody titres and risk of febrile malaria
Anti-MSP3 antibody titres were significantly associated with an increased hazard of the first febrile malaria episode on univariate (Table S4) and multivariable analysis (Table 3). There was no evidence of association between anti-GLURP antibody titres and varying malaria risk. The baseline anti-malaria antibody titres for both antigens did not show any significant association with the risk of febrile malaria. The wet season and individual malaria exposure index were associated with higher risk of febrile malaria. The
baseline foetal haemoglobin fraction showed a protective effect in the multivariable model (HR = 0.97, \( p = 0.003 \), 95% CI [0.96, 0.99]) which was not significant in univariate analysis (Table S3). This was dependent on adjusting for exposure index in the multivariable model, and we noted a non-significant association between foetal haemoglobin and exposure index (r = 0.17, \( p = 0.064 \)). Belonging to the haemoglobin CC type group was also significantly associated with decreased malaria incidence (IRR = 0.44, \( p = 0.046 \), 95% CI [0.19, 0.99]) in the multivariable but not in the univariate analysis.

We did not detect significant variation in the proportionality of hazards over time (Figure 2, Figure S4), but there was borderline variation in varying hazards for the exposure index (\( p = 0.082 \), in the direction of decreasing hazard over time) and for foetal haemoglobin (\( p = 0.098 \), in the direction of increasing hazard over time).

Table 1. Baseline characteristics of the study population.

| Characteristic                          | Statistic                      |
|----------------------------------------|--------------------------------|
| Male_freq(%)                           | 67 (47.9%)                     |
| Age infants[days]_median [min, max]    | 33 [27,42]                     |
| Weight [kg]_median [min, max]          | 4.1 [2.8, 5.9]                 |
| Length [cm]_median [min, max]          | 54 [46, 61]                    |
| MUAC [cm]_median [min, max]            | 12 [8.5, 16]                   |
| Hb rate [g/dL]_median [min, max]       | 12.6 [8.7, 17.6]               |
| Foetal Hb [%]_median [min, max]        | 59.6 [20.1, 89.6]              |
| Hb phenotype_freq (%)                  |                                |
| AA                                     | 113 (80.71)                    |
| AC                                     | 18 (13.14)                     |
| AS                                     | 1 (0.73)                       |
| CC                                     | 5 (3.65)                       |
| Delivery way                          |                                |
| Natural                                | 133 (95)                       |
| Cesarian section                      | 5 (3.6)                        |
| Neonatal resuscitation_freq (%)       | 12 (8.8)                       |
| Neonatal infection_freq (%)           | 2 (1.43)                       |
| EPI (up to date at 1 month)_freq (%)  | 124 (88.6)                     |
| Age groups mothers (years)_freq (%)   |                                |
| \( \leq 19 \)                          | 10 (7.1)                       |
| 20–29                                  | 89 (63.6)                      |
| \( \geq 30 \)                          | 37 (26.4)                      |
| ITN use (during pregnancy)_freq (%)   | 123 (87.9)                     |
| IPTp courses_freq (%)                  |                                |
| 0                                      | 10 (7.14)                      |
| 1                                      | 28 (20)                        |
| 2                                      | 100 (71.43)                     |
| 3                                      | 2 (1.43)                       |
| Gravidity status_freq (%)              |                                |
| primigravidae                          | 32 (22.86)                     |
| multigravidae                          | 106 (75.71)                    |
| Education level (mothers)_freq (%)     |                                |
| No formal education                    | 78 (55.71)                     |
| Primary school                         | 39 (27.86)                     |
| Secondary school or above              | 22 (15.71)                     |
| Distribution of study population       |                                |
| Bounouna                               | 34 (22.97)                     |
| Nafona                                  | 41 (27.7)                      |
| Korona                                  | 16 (10.81)                     |
| Flantama                                | 49 (33.11)                     |

1. Number of missing data.
2. doi:10.1371/journal.pone.0107965.t001
The results of negative binomial regression were consistent with the Cox regression analysis (Table 3). The best fit lines from the multivariable fractional polynomial regression are consistent with a linear effect of antibody titres on febrile malaria episodes (Figure S6). Changing anti-MSP3 antibody titres were significantly associated with increased incidence of febrile malaria episodes (IRR = 1.17, p = 0.007, 95% CI [1.04, 1.30]), but baseline titres were not. Changing Anti-GLURP R0 antibody titres were significantly associated with increased incidence of febrile malaria on univariate (Table S4) but not multivariable analysis (Table 3). Age, season and individual malaria exposure index were significantly associated with increased incidence of febrile malaria episodes. We examined interaction terms: we found that the effects of total IgG to the malaria antigens we tested were not additive, and noted an interaction between malaria exposure index and total IgG to MSP3 of marginal significance (Table S7).

Restricting the observation period to six weeks post bleeding for plasma, to take into account the fact that anti-malaria antibodies are more likely to be short-lived in young children [50], yielded stronger associations in univariate analysis but not in the multivariable analysis and not in the direction of protection (Table S5).

Discussion

In this study, transplacentally acquired anti-malaria antibodies and foetal haemoglobin were investigated in relation to susceptibility to malaria in a cohort of 140 infants. Antibody titres to GLURP and MSP3 were found to decline in the first four months of life, presumably due to the loss of maternal antibodies. Endogenous production was responsible for the subsequent increase in the case of GLURP and stabilisation of the loss of antibodies for MSP3. Contrary to our expectations, there was no association between antibody titres to GLURP (R0 and R2) and the risk of febrile malaria in the first two years of life; antibody titres to MSP3 even appeared as a marker of exposure since it was statistically significantly positively associated with the incidence of febrile malaria and inversely associated with time to first febrile malaria episode. Confounding between malaria risk and antibody titre by variation in exposure has previously been reported [51,52].

In the investigation of the role of antibodies to MSP3 and GLURP (R0 and R2) against *P. falciparum* malaria, most of the previous studies did not specifically target infants. A number of prospective sero-epidemiological studies have investigated the role of antibodies to these merozoite surface antigens in older children and adults in West Africa, East Africa as well as South-East Asia.

The lack of association between antibodies to GLURP (R0 and R2) and protection against clinical malaria in our study is partially concordant with the findings of a previous study in older children in Burkina Faso. Nebie and colleagues investigated total IgG to GLURP (R0 and R2) among others antigens in children aged 6 months to 10 years and found a protective effect for antibodies to GLURP (R0) but not to GLURP (R2) when the antibody titres were analysed individually. When antibody titres to all the four antigens studied (NANP, GLURP R0 and R2, MSP3) were included in a multivariable model, antibodies to GLURP (R0 and R2) were not associated with protection against malaria [24]. In Ghana, Dodoo and colleagues reported a protective effect of total IgG and IgG subclasses to GLURP (R0 and R2) in the univariate analysis. However neither total IgG nor IgG subclasses to GLURP (R0 and R2) were significantly protective when all the serological covariates
Table 2. Multivariable predictive model for changing anti-malaria antibody titres.

| Predictor                  | IgG anti-MSP3 |         |         |         | IgG anti-GLURP R0 |         |         |         | IgG anti-GLURP R2 |         |         |
|----------------------------|---------------|---------|---------|---------|------------------|---------|---------|---------|------------------|---------|---------|
|                            | Coef.         | 95% CI  | p       |         | Coef.            | 95% CI  | p       |         | Coef.            | 95% CI  | p       |
| Age power                  | 0.02          | [0.02, 0.03] | <0.001 |         | 2                | [1.49, 2.50] | <0.001 |         | -2.04           | [-2.98, -1.10] | <0.001 |
| (NA/0/2/5)                 | -             |         |         |         | -                |         |         |         | -0.92           | [-1.21, -0.62] | <0.001 |
| ITN use (pregnancy)        |               |         |         |         | -                |         |         |         | -0.11           | [-0.49, 0.26] | 0.548   |
| Yes                        | 0             |         |         |         | 0.16             | [-0.22, 0.53] | 0.413 | -0.01             | [0.17, 0.39] | <0.001 |
| No                         | -0.11         | [-0.49, 0.26] | 0.548 |         | 0                | [-0.22, 0.53] | 0.413 | 0.02             | [-0.44, 0.48] | 0.918  |
| Season                     |               |         |         |         | 0.35             | [0.13, 0.57] | 0.002 | 0.33             | [0.19, 0.47] | <0.001 |
| Dry season                 | 0             | -       |         |         | 0.33             | [0.19, 0.47] | 0.001 | 0.28             | [0.07, 0.50] | 0.011  |
| Rains                      | 0.02          | [-0.003, 0.04] | 0.098 |         | -0.01           | [-0.03, 0.006] | 0.202 | 0.01             | [-0.01, 0.04] | 0.393  |
| Malaria Exposure index     | 0.12          | [-0.002, 0.24] | 0.053 |         | 0.28             | [0.17, 0.39] | <0.001 | 0.31             | [0.17, 0.45] | <0.001 |
| Number previous infections |               |         |         |         | -                |         |         |         |                  |         |         |

*Age is transformed in multiple fractional polynomials with the corresponding powers for antibodies to MSP3, GLURP R0 and GLURP R2 indicated in brackets.

*Number of malaria infections recorded between two consecutive time points for antibody titres measurement.

doi:10.1371/journal.pone.0107965.t002
were taken into account in the final multivariable model [19,25]. In a study conducted in Tanzania by Lusingu and colleagues, total IgG to GLURP R0 was not associated with protection against febrile malaria; among IgG subclasses only IgG1 was associated with protection. In contrast, other studies have demonstrated a protective association for antibodies to GLURP (R0 and R2) in older children and adults [20,26,27,30]. In a study in Myanmar that investigated antibodies to MSP1, MSP3, GLURP (R0, R1, R2), only antibodies to GLURP R0 showed a protective effect when all the antibodies were considered together in the analysis [21].

Antibodies to MSP3 have been associated with protection in previous sero-epidemiological studies [21,23,27,53] and a vaccine trial [44] even if the assessment of efficacy was not the primary objective in the latter. However other studies did not find a protective effect of antibodies to MSP3 [19,25,26] but none of these studies concluded on antibodies to MSP3 appearing as a marker of exposure.

Although antibodies to MSP3 and GLURP have not been previously studied in newborn cohorts, antibodies to other *P. falciparum* malaria antigens have been investigated. In sero-epidemiological newborn cohort studies, antibodies to crude *P. falciparum* schizont extract and MSP2 were found to be associated with higher risk of malaria infection in infants [38,40] indicating higher exposure. Only antibodies to MSP1-19 were associated with protection against clinical malaria [42,43].

Antibody titres to MSP3 and GLURP (R0 and R2) were not associated with protection in our study, and we suggest that confounding due to exposure led to an apparent association with increased susceptibility for antibody response to MSP3. Limitations of our study include the fact that the high malaria transmission season began 5–7 months after recruitment. Therefore the majority of the maternal antibodies were likely gone by the time that febrile malaria episodes began, and children were exposed during a period of lower antibody titres. We did not use an external control to quantify malaria antibodies as performed elsewhere [54], however we speculate that antibody titres at 5 months and beyond were lower than those previously reported to be protective [42,43].

Interestingly, foetal haemoglobin was significantly inversely associated to febrile malaria incidence although the effect size was relatively small. The effect was only statistically significant on multivariable analysis, and appeared to depend on adjusting by exposure index in the multivariable model. Furthermore the effect seems to be evident after 6 months of age, when we would expect foetal haemoglobin to have been lost from the circulation. We speculate that an interaction between malaria exposure and foetal haemoglobin may be responsible for a delayed protective effect, perhaps due to an early but controlled infection in the presence of high levels of foetal haemoglobin leading to more rapid acquisition of immunity [55].

Children who carried the haemoglobin CC type appeared to have a significantly lower risk of malaria as compared to haemoglobin AA type children, as has been previously reported [56,57].

In conclusion, the present study did not find any evidence of association between antibody titres to MSP3 and GLURP (R0 and R2) and protection against *P. falciparum* febrile malaria in

---

**Table 3. Multivariable models of risk of malaria using changing anti-malaria antibody titres.**

| Predictor | Cox regression | Negative binomial regression |
|-----------|----------------|-------------------------------|
|           | HR[^d^] 95%CI | P | IRR[^e^] 95%CI | P |
| Age       | NA - - | 1.11 [1.09, 1.13] | <0.001 |
| MUAC[^a^] (baseline) | - - | 1.26 [1.09, 1.45] | 0.002 |
| Foetal Hb[^b^] rate (baseline) | 0.97 [0.96, 0.99] | 0.033 | 0.98 [0.97, 0.99] | 0.013 |
| Haemoglobin type |  | | | |
| AA | - - | 1 - - | - - |
| AS[^c^] | NA[^c^] - | - | NA[^c^] - - |
| AC | 1.29 [0.68, 2.47] | 0.430 | 1.14 [0.75, 1.72] | 0.540 |
| CC | 0.52 [0.12, 2.19] | 0.370 | 0.44 [0.19, 0.99] | 0.046 |
| Anti-MSP3 (changing) | 1.34 [1.08, 1.66] | 0.007 | 1.17 [1.04, 1.30] | 0.007 |
| Anti-GLURP R0 (changing) | 1.15 [0.91, 1.44] | 0.233 | 1.003 [0.88, 1.14] | 0.968 |
| Anti-GLURP R2 (changing) | 0.98 [0.83, 1.16] | 0.859 | 0.92 [0.82, 1.03] | 0.149 |
| ITN use (pregnancy) |  | | | |
| Yes | 1 - - | 1 | - - |
| No | 0.86 [0.41, 1.79] | 0.687 | 1.23 [0.80, 1.88] | 0.348 |
| Season |  | | | |
| Dry season | 1 - - | 1 | - - |
| Rains | 10.85 [2.80, 42.15] | 0.001 | 1.4 [1.02, 1.92] | 0.037 |
| Malaria Exposure index | 1.08 [1.04, 1.13] | <0.001 | 1.06 [1.03, 1.09] | <0.001 |

[^a^]MUAC: mid upper arm circumference.  
[^b^]Hb: haemoglobin.  
[^c^]NA not applicable; only one child had haemoglobin AS type.  
[^d^]HR: hazard ratio.  
[^e^]IRR: incidence rate ratio.  
[^f^]There was no collinearity between the predictors (Figure S5, Table S6).  
[^g^]doi:10.1371/journal.pone.0107965.t003
children in their first few months of life. Despite the above mentioned limitations of the study, the baseline fraction of foetal was associated with protection against febrile malaria. Its role in the protection of children against malaria in their first few months of life is therefore worthy of further investigation. Finally, our study also underlines that the role of haemoglobinopathies should be taken into account in the exploration of protective factors in the low susceptibility of infants to malaria.

Acknowledgments

We are grateful to the parents/guardians of the children in Banfora whose commitment and patience made this study possible. We thank the fieldworkers’ team and nurses in the dispensaries who monitored these children for two years as well as all the lab staff. We would also like to especially thank Dr Michael Theisen who kindly provided the malaria antigens used in this study, MSP3-LSP, GLURP R0 and GLURP R2.

Supporting Information

Figure S1 Distribution of parasitemia in febrile and afebrile children for the whole study period. The box-and-whisker plot represents the median and the inter-quartile range of the parasite density in a log 10 scale in the febrile and afebrile children groups.

Figure 2. Effect of antibody titres, individual malaria exposure index and baseline foetal haemoglobin rate on survival to malaria: Kaplan Meier estimates. (A) Antibodies to MSP3, (B) Antibodies to GLURP R0, (C) Antibodies to GLURP R2, (D) Individual malaria exposure index, (E) Foetal haemoglobin fraction.

doi:10.1371/journal.pone.0107965.g002

Figure S2 Selection of the best radius for individual malaria exposure index calculation. The lowest log likelihood in the univariate Cox regression analysis was the selection criteria for the radius to be used.

Figure S3 Dynamics of total IgG to MSP3 over the whole study period using a 25% random sample representing 23 children. Each line represents a child. The antibody titres are in log 10 scale.

Figure S4 Test of proportional hazards assumption: Schoenfeld residuals plots. (A) Baseline total IgG to MSP3, (B) Baseline total IgG to GLURP R0, (C) Baseline total IgG to GLURP R2, (D) Changing total IgG to MSP3, (E) Changing total IgG to GLURP R0, (F) Changing total IgG to GLURP R2, (G) Individual malaria exposure index, (H) Baseline Foetal haemoglobin rate.

Figure S5 Scatter plot matrix of the continuous independent variables used used in multivariable regression models.

Figure S6 Multivariable fractional polynomial plots for antibodies to MSP3 (A), GLURP R0 (B) and GLURP R2 (C).
Table S1 Predictive model for the occurrence of febrile malaria episodes using antibody titres with a restricted observation period (6 weeks) post-bleeding for plasma. (DOCX)

Table S2 Predictive model for changing anti-malaria antibody titres using linear regression. Univariate analysis. (DOCX)

Table S3 Cox regression analysis using changing antibody titres. (DOCX)

Table S4 Predictive model for the occurrence of febrile malaria episodes using changing antibody titres. (DOCX)

Table S5 Predictive model for the occurrence of febrile malaria episodes using changing antibody titres with a restricted observation period (6 weeks) post-bleeding for plasma. (DOCX)

Table S6 Multicollinearity diagnostics for continuous independent variables used in multivariable regression models. (DOCX)

Table S7 Testing for interactions between predictors in multivariable negative binomial regression model. (DOCX)

Author Contributions
Conceived and designed the experiments: IN AT SBS. Performed the experiments: JK JY SD ST OO GS. Analyzed the data: DK PB. Contributed to the writing of the manuscript: DK IN JY SD ST OO GS IS AD AT KM SBS PB.

References
1. WHO (2012) World Malaria Report 2012. Available: http://www.who.int/malaria/publications/world_malaria_report_2012/report/en/. Accessed 2013 December.
2. MacDonald G (1950) The analysis of malaria parasite rates in infants. Trop Dis Bull 47: 943–950.
3. Bruce-Chwatt LJ (1952) Malaria in African children and children in Southern Nigeria. Ann Trop Med Parasitol 46: 173–200.
4. Brabin B (1990) An analysis of malaria parasite rates in infants: 40 years after MacDonald. Trop Dis Bull 87: 20.
5. Snow RW, Nahlen B, Palmer A, Donnelly CA, Gupta S, et al. (1998) Risk of severe malaria among African infants: direct evidence of clinical protection during early infancy. J Infect Dis 177: 819–822.
6. Cohen S, Mc GI, Carrington S (1961) Gamma-globulin and acquired immunity to human malaria. Nature 192: 733–737.
7. Erdouzen JC, Gilles HM, Udeozo IOK (1962) Adult And Cord-Blood Gamma Globulin and Immunity to Malaria in Nigerians. The Lancet 280: 951–956.
8. McGregor IG, Carrington SP, Cohen S (1963) Treatment of East African F. falciparum malaria with West African human yglobulin. Transactions of The Royal Society of Tropical Medicine and Hygiene 57: 170–175.
9. Sahaheareon A, Burnout T, Ouattara D, Attanath P, Bouharoun-Tayoun H, et al. (1991) Paratroposide and clinical human response to immunoglobulin administration in falciparum malaria. Am J Trop Med Hyg 45: 297–308.
10. Pared G, Weatherall DJ, Wilson RJ, Smith DH, Gilles HM (1976) Fetal haemoglobin and malaria. Lancet 1: 1269–1272.
11. Amaratunga C, Lopera-Mesa TM, Brittain NJ, Cholera R, Arie T, et al. (2011) Protection and Vaccine Development Against Plasmodium falciparum Malaria. PLoS Med 8: e1001051.
12. Shear HL, Grinberg I, Gilman J, Fabre MY, Stamatoyannopoulos G, et al. (1998) Transgenic mice expressing human fetal globin are protected from homologous Plasmodium falciparum infection. Proc Natl Acad Sci USA 95: 7439–7443.
13. Kicska GA, Ting LM, Schramm VL, Kim K (2003) Effect of dietary p-aminobenzoinic acid on murine Plasmodium yoelli infection. J Infect Dis 188: 1776–1781.
14. Magerath RG, Deegan T, Jones ES (1952) Suppression of malaria (P. berghii) by milk. Br Med J 2: 1302–1304.
15. Hawking F (1954) Milk, p-aminobenzoate, and malaria of rats and monkeys. Br Med J 1: 423–429.
16. Jacobs R (1968) Role of P-Aminobenzoic Acid in Plasmodium Berghei Infection in the Mouse. Exp Parasitol 15: 213–225.
17. Kassim O, Ako-Anai K, Torimiro S, Hollowell G, Okoye V, et al. (2000) Impact of age of first exposure to Plasmodium falciparum on antibody responses to malaria in children: a randomized, controlled trial in Mosambique. Malar J 1: 108.
18. Mularihead-Thomson RC (1951) The distribution of anopheline mosquito bites during early infancy. J Infect Dis 177: 819–822.
19. Dodoo D, Theisen M, Kurtzhals JAL, Akanmori BD, Koram KA, et al. (2000) Maternal Antibodies to Malaria in Children Aged 0-2 Years. J Infect Dis 181: 1202–1205.
20. Dziegiel M, Rowe P, Bennett S, Allen SJ, Olerup O, et al. (1993) Immunoassay of the Glutamate-Rich Protein Are Associated with Protection from Plasmodium falciparum malaria. J Infect Dis 168: 1767–1781.
21. Evans WH, Schelling KG, Torda AE (1981) Role of F-Aminobenzoic acid in Plasmodium berghei Infection in the Mouse. Exp Parasitol 15: 213–225.
22. Mamo H, Esern M, Ajaa A, Thenien M, Mordomuller B, et al. (2011) Humoral immune response to Plasmodium falciparum vaccine candidate GM2 and its components in populations naturally exposed to seasonal malaria in Ethiopia. Malar J 12: 51.
23. Oster HHA, Fegan G, Polley SD, Murungi L, Verra F, et al. (2008) Breadth and Magnitude of Antibody Responses to Multiple Plasmodium falciparum Merozoite Antigens Are Associated with Protection from Clinical Malaria. Infection and Immunity 76: 2240–2248.
24. Dodoo D, Theisen M, Kurtzhals JAL, Akanmori BD, Koram KA, et al. (2000) Naturally Acquired Antibodies to the Glutamate-Rich Protein Are Associated with Protection against Plasmodium falciparum Malaria. Journal of Infectious Diseases 181: 1202–1205.
25. Dziegiel M, Rowé P, Bennett S, Allen SJ, Olerup O, et al. (1993) Immunoglobulin M and G antibody responses to Plasmodium falciparum glutamate-rich protein: correlation with clinical immunity in Gambian children. Infection and Immunity 61: 103–108.
26. Hög B, Petersen E, Dziegiel M, David K, Hanson A, et al. (1992) Antibodies to a Recombinant Glutamate-Rich Plasmodium Falciparum Protein: Evidence for Protection of Individuals Living in a Holoendemic Area of Liberia. The American Journal of Tropical Medicine and Hygiene 46: 307–313.
27. Williams AM, McFarlane H (1969) Distribution of malarial antibody in maternal and cord sera. Arch Dis Childh. 511–514.
28. Nhabomba A, Guinovart C, Jimenez A, Manaca M, Quinto L, et al. (2014) Impact of age of first exposure to Plasmodium falciparum on antibody responses to malaria in children: a randomized, controlled trial in Mozambique. Malar J 13: 121.
29. Petesouk S, Suguitan AL, Long C, Leke RGF, Taylor DW (2007) Fetal Immune Responses to Plasmodium falciparum Antigens in a Malaria-Endemic Region of Cameroon. The Journal of Immunology 178: 2779–2777.
30. May K, Grube M, Malikova I, Long CA, Singh S, et al. (2009) Antibody-Dependent Transplacental Transfer of Malaria Blood-Stage Antigen Using a Human Ex Vivo Placental Perfusion Model. PLoS ONE 4: e7696.
37. Achidi EA, Salimonu LS, Perlmann H, Perlmann P, Berzins K, et al. (1996) Lack of association between levels of transplacentally acquired Plasmodium falciparum-specific antibodies and age of onset of clinical malaria in infants in a malaria endemic area of Nigeria. Acta Trop 61: 315–326.

38. Wagner G, Koram K, McGuinness D, Bennett S, Nkrumah F, et al. (1998) High incidence of asymptomatic malaria infections in a birth cohort of children less than one year of age in Ghana, detected by multiplex gene polymerase chain reaction. The American Journal of Tropical Medicine and Hygiene 59: 115–123.

39. Kitua AY, Urassa H, Wechsler M, Smith T, Vounatsou P, et al. (1999) Antibodies against Plasmodium falciparum vaccine candidates in infants in an area of intense and perennial transmission: relationships with clinical malaria and with entomological inoculation rates. Parasite Immunol 21: 307–317.

40. Riley EM, Wagner GE, Ofori MF, Wheeler JG, Akanmori BD, et al. (2000) Lack of association between maternal antibody and protection of African infants from malaria infection. Infect Immun 68: 5856–5863.

41. Zhou Z, Xiao L, Branch OH, Kariuki S, Nahlen BL, et al. (2002) Antibody responses to repetitive epitopes of the circumsporozoite protein, liver stage antigen-1, and merozoite surface protein-2 in infants residing in a Plasmodium falciparum-hyperendemic area of western Kenya. XIII. Asembo Bay Cohort Project. Am J Trop Med Hyg 66: 7–12.

42. Hogh B, Marbiah NT, Burghaus PA, Andersen PK (1995) Relationship between maternally derived anti-Plasmodium falciparum antibodies and risk of infection and disease in infants living in an area of Liberia, west Africa, in which malaria is highly endemic. Infect Immun 63: 4034–4038.

43. Branch OH, Udhayakumar V, Highetower AW, Olool AJ, Haswely WA, et al. (1998) A longitudinal investigation of IgG and IgM antibody responses to the merozoite surface protein-1 19-kDa/Dalton domain of Plasmodium falciparum in pregnant women and infants: associations with febrile illness, parasitemia, and anemia. Am J Trop Med Hyg 58: 211–219.

44. Sirima SB, Coures S, Druilhe P (2011) Protection against malaria by MSP3 candidate vaccine. N Engl J Med 365: 1062–1064.

45. Belard S, Isolou S, Hounkpatin AB, Schaumburg F, Ngou UA, et al. (2011) A randomized controlled phase Ib trial of the malaria vaccine candidate GMZ2 in African children. PLoS One 6: e22525.

46. Tiono AB, Kangoye DT, Rehman AM, Kargroupou DG, Kabore Y, et al. (2014) Malaria incidence in children in South-West burkina faso: comparison of active and passive case detection methods. PLoS One 9: e86936.

47. Druilhe P, Sperini F, Sceooe D, Corrado G, Mejia P, et al. (2005) A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum. PLoS Med 2: e344.

48. Theisen M, Vuust J, Gottschau A, Jepsen S, Hough B (1995) Antigenicity and immunogenicity of recombinant glutamate-rich protein of Plasmodium falciparum expressed in Escherichia coli. Clin Diagn Lab Immunol 2: 30–34.

49. Olotu A, Fegan G, Wambua J, Nyangweso G, Ogada E, et al. (2012) Estimating individual exposure to malaria using local prevalence of malaria infection in the field. PLoS One 7: e32929.

50. Kinyanjui S, Bejon P, Osiar F, Bull P, Marsh K (2009) What you see is not what you get: implications of the brevity of antibody responses to malaria antigens and transmission heterogeneity in longitudinal studies of malaria immunity. Malaria Journal 8: 242.

51. Bejon P, Cook J, Bergmann-Leitner E, Olotu A, Lusingu J, et al. (2011) Effect of the pre-erythrocytic candidate malaria vaccine RTS,S/AS01E on blood stage immunity in young children. J Infect Dis 204: 9–18.

52. Greenhouse B, Ho B, Hubbard A, Njama-Meya D, Narum DL, et al. (2011) Antibodies to Plasmodium falciparum antigens predict a higher risk of malaria but protection from symptoms once parasitemic. J Infect Dis 204: 19–26.

53. Osier FH, Fegan G, Polley SD, Murungi L, Verra F, et al. (2008) Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria. Infect Immun 76: 2240–2248.

54. Murungi LM, Kamuyu G, Lowe B, Bejon P, Theisen M, et al. (2013) A threshold concentration of anti-merozoite antibodies is required for protection from clinical episodes of malaria. Vaccine 31: 3936–3942.

55. Pombo DJ, Lawrence G, Hirunpetcharat C, Rzepczyk C, Bryden M, et al. (2002) Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet 360: 610–617.

56. Modiano D, Laoung S, Siruma BS, Simpore J, Verra F, et al. (2001) Haemoglobin C protects against clinical Plasmodium falciparum malaria. Nature 414: 305–308.

57. Bougouna EC, Tiono AB, Ouendraso G, Soulama I, Diarra A, et al. (2012) Haemoglobin variants and Plasmodium falciparum malaria in children under five years of age living in a high and seasonal malaria transmission area of Burkina Faso. Malar J 11: 154.